Bain Capital managing partner David Gross on Japan private equity, roll-up strategies, and why macro now matters as much as micro

David Gross, Bain Capital: Japan, roll-ups, and the macro turn

David Gross has spent two decades building Bain Capital's Japan franchise, starting with his first visit in 1989 when Japan was seen as an economic threat to the US. What drew him there — curiosity about a rival system — eventually became the template for how Bain approached private equity in a market that most Western firms found impenetrable.

Early Japan playbook

The initial assumption was that Bain would target large, globally connected Japanese businesses. That turned out to be wrong. Currency exposure and competition from Chinese manufacturers made those deals harder to manage. The firm pivoted to domestic, insulated businesses: restaurants, food companies, hotels, a mushroom producer. The logic was straightforward — control the macro variables, then run the operations better. Only after ten to fifteen deals, and roughly ten to fifteen years of market-building, did Bain get access to the bigger technology assets, including Kyocera's semiconductor business and Evident, a high-precision instruments company.

Talent was the constraint throughout. In the mid-2000s, Japan had no established pool of well-rounded deal professionals. Bain hired specialists — dedicated sourcers, dedicated operating people — and trained them separately before pushing them to work together. The model was a workaround, not a preference, and Gross says it took years to produce the kind of generalist investor the firm wanted.

“We started as a private equity firm but actually our roots were in growth capital. Our first investment was Staples when it had like five stores. ... The ability to use AI to each step of that process to really turbocharge what we're doing, that will be the future. ... We have 600 businesses across the economy. We're in credit. We're in venture. We're in life sciences. We're in private equity.”

Private equity versus venture

Gross is candid that venture requires a different cognitive model. In buyouts, you have historical financials, operational levers, and clear control rights. In venture, you're evaluating founder adaptability with almost no prior data. Bain runs separate investment committee processes for its venture and life sciences teams — the latter staffed almost entirely by MD/PhDs making judgments on clinical probabilities — while trying to bring platform benefits across all of them: relationships with the top 15 pharma companies, capital markets access, introductions to large enterprise customers.

On mistakes, Gross doesn't focus on the loss rate. Venture is designed for high numerical failure, and he's explicit that batting average is the wrong metric. What Bain tracks closely are the deals that got away — investments the firm passed on that performed. The process involves color-coding every deal done across the market (green, yellow, red) and reviewing them to identify systematic biases in how the team discounts or over-weights certain factors.

Roll-ups and the Bending Spoons question

Gross sees roll-up strategies as neither inherently good nor bad. The 1980s and 1990s US experience showed that buying fragmented industries and stacking companies together only worked if margins actually improved — when the thesis was purely multiple arbitrage, it failed. What he finds genuinely interesting about Bending Spoons and similar firms is the technology-first operating model: using AI at each step of sourcing and value creation rather than just as a back-office add-on.

Bain's dedicated value creation team numbers close to 400 people. Gross argues that applying AI across that whole process is the real opportunity, and says Bain is studying pure-play firms that have built around that approach.

The macro turn

For most of its history, Bain positioned itself as a micro-focused firm — operating improvements, management teams, company-level decisions. The 2008 financial crisis was the first signal that macro factors could overwhelm even well-run portfolio companies. Gross says the firm has since built a standalone macroeconomic team with PhD-level economists and specialists in energy markets, housing, and other sectors. That team produces an independent view of the economy; deal teams then take that view and apply it at the sector and company level.

The edge Bain is trying to build is speed. With roughly 600 businesses across private equity, credit, venture, and life sciences, the firm's portfolio is large enough to generate real-time signals on labor costs and input prices faster than competitors or public market data. If inflationary trends show up in the portfolio before they appear in published data, that's a potential intervention window.

The shift from micro to macro as a core competency is arguably the most structural change Gross describes — a recognition that in a more volatile world, the analytical skills that win deals are no longer sufficient to protect them.